Glycoform and net charge heterogeneity in gp120 immunogens used in HIV vaccine trials.
<h4>Background</h4>The RV144 clinical trial showed for the first time that vaccination could provide modest but significant protection from HIV-1 infection. To understand the protective response, and to improve upon the vaccine's efficacy, it is important to define the structure of...
Guardado en:
Autores principales: | Bin Yu, Javier F Morales, Sara M O'Rourke, Gwen P Tatsuno, Phillip W Berman |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2012
|
Materias: | |
Acceso en línea: | https://doaj.org/article/34b4ba247fa246ce969cefb256a8b7db |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
HIV-1 gp120 mannoses induce immunosuppressive responses from dendritic cells.
por: Meimei Shan, et al.
Publicado: (2007) -
Identification and characterization of a broadly cross-reactive HIV-1 human monoclonal antibody that binds to both gp120 and gp41.
por: Mei-Yun Zhang, et al.
Publicado: (2012) -
Release of gp120 Restraints Leads to an Entry-Competent Intermediate State of the HIV-1 Envelope Glycoproteins
por: Alon Herschhorn, et al.
Publicado: (2016) -
Native mass spectrometry combined with enzymatic dissection unravels glycoform heterogeneity of biopharmaceuticals
por: Therese Wohlschlager, et al.
Publicado: (2018) -
Conserved B-cell epitope identification of envelope glycoprotein (GP120) HIV-1 to develop multi-strain vaccine candidate through bioinformatics approach
por: Viol Dhea Kharisma, et al.
Publicado: (2021)